PDCD1 and cancer: In line with this, an increase in Treg frequencies was observed upon anti-PD1 treatment in leukapheresis specimens of non-responders in advanced melanoma patients [51], further indicating the resilience of Tregs in cancer is proving to be a prickle in anti-PD1 efficiency.